ALK-Abelló Past Earnings Performance
Past criteria checks 4/6
ALK-Abelló has been growing earnings at an average annual rate of 67.9%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 10.4% per year. ALK-Abelló's return on equity is 10.9%, and it has net margins of 10.1%.
Key information
67.9%
Earnings growth rate
68.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 10.4% |
| Return on equity | 10.9% |
| Net Margin | 10.1% |
| Next Earnings Update | 03 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ALK-Abelló makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,824 | 486 | 1,753 | 618 |
| 30 Sep 23 | 4,728 | 424 | 1,700 | 652 |
| 30 Jun 23 | 4,680 | 359 | 1,722 | 664 |
| 31 Mar 23 | 4,590 | 335 | 1,702 | 666 |
| 31 Dec 22 | 4,511 | 335 | 1,656 | 665 |
| 30 Sep 22 | 4,361 | 333 | 1,641 | 658 |
| 30 Jun 22 | 4,227 | 318 | 1,586 | 644 |
| 31 Mar 22 | 4,050 | 255 | 1,499 | 654 |
| 31 Dec 21 | 3,916 | 219 | 1,463 | 630 |
| 30 Sep 21 | 3,808 | 112 | 1,442 | 611 |
| 30 Jun 21 | 3,652 | 55 | 1,385 | 585 |
| 31 Mar 21 | 3,556 | 66 | 1,359 | 516 |
| 31 Dec 20 | 3,491 | 25 | 1,363 | 496 |
| 30 Sep 20 | 3,383 | 43 | 1,347 | 486 |
| 30 Jun 20 | 3,350 | 49 | 1,389 | 489 |
| 31 Mar 20 | 3,363 | -9 | 1,439 | 480 |
| 31 Dec 19 | 3,274 | -50 | 1,461 | 466 |
| 30 Sep 19 | 3,178 | -183 | 1,470 | 425 |
| 30 Jun 19 | 3,100 | -200 | 1,442 | 385 |
| 31 Mar 19 | 3,030 | -149 | 1,412 | 377 |
| 31 Dec 18 | 2,915 | -170 | 1,366 | 360 |
| 30 Sep 18 | 2,891 | -183 | 1,336 | 395 |
| 30 Jun 18 | 2,897 | -152 | 1,327 | 399 |
| 31 Mar 18 | 2,873 | -136 | 1,314 | 410 |
| 31 Dec 17 | 2,910 | -158 | 1,298 | 426 |
| 30 Sep 17 | 2,901 | 37 | 1,233 | 386 |
| 30 Jun 17 | 2,864 | 76 | 1,175 | 383 |
| 31 Mar 17 | 2,946 | 149 | 1,133 | 383 |
| 31 Dec 16 | 3,005 | 270 | 1,091 | 385 |
| 30 Sep 16 | 2,938 | 373 | 1,063 | 406 |
| 30 Jun 16 | 2,975 | 396 | 1,055 | 412 |
| 31 Mar 16 | 2,767 | 378 | 1,038 | 416 |
| 31 Dec 15 | 2,569 | 344 | 1,033 | 407 |
| 30 Sep 15 | 2,494 | 221 | 1,029 | 399 |
| 30 Jun 15 | 2,349 | 185 | 1,018 | 396 |
| 31 Mar 15 | 2,399 | 162 | 1,011 | 392 |
| 31 Dec 14 | 2,433 | 181 | 996 | 394 |
| 30 Sep 14 | 2,414 | 205 | 954 | 374 |
| 30 Jun 14 | 2,401 | 188 | 955 | 381 |
| 31 Mar 14 | 2,318 | 127 | 948 | 420 |
| 31 Dec 13 | 2,244 | 61 | 955 | 463 |
| 30 Sep 13 | 2,266 | 6 | 965 | 502 |
| 30 Jun 13 | 2,365 | 53 | 978 | 520 |
Quality Earnings: 0OIR has high quality earnings.
Growing Profit Margin: 0OIR's current net profit margins (10.1%) are higher than last year (7.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0OIR has become profitable over the past 5 years, growing earnings by 67.9% per year.
Accelerating Growth: 0OIR's earnings growth over the past year (45.1%) is below its 5-year average (67.9% per year).
Earnings vs Industry: 0OIR earnings growth over the past year (45.1%) exceeded the Pharmaceuticals industry 4%.
Return on Equity
High ROE: 0OIR's Return on Equity (10.9%) is considered low.